Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1985 1
1991 1
1994 2
1996 3
1998 1
2000 5
2001 1
2002 2
2003 1
2004 1
2005 3
2006 2
2008 6
2009 3
2010 5
2011 11
2012 7
2013 8
2014 9
2015 4
2016 3
2017 8
2018 3
2019 6
2020 8
2021 8
2022 7
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
The intersection of COVID-19 and autoimmunity.
Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, Hanauer DA, James JA, Kanthi Y, Ladd V, Mehta P, Ring AM, Sanz I, Selmi C, Tracy RP, Utz PJ, Wagner CA, Wang JY, McCune WJ. Knight JS, et al. Among authors: fox se. J Clin Invest. 2021 Dec 15;131(24):e154886. doi: 10.1172/JCI154886. J Clin Invest. 2021. PMID: 34710063 Free PMC article. Review.
Acute COVID-19, caused by SARS-CoV-2, is characterized by diverse clinical presentations, ranging from asymptomatic infection to fatal respiratory failure, and often associated with varied longer-term sequelae. Over the past 18 months, it has become apparent that inappropr …
Acute COVID-19, caused by SARS-CoV-2, is characterized by diverse clinical presentations, ranging from asymptomatic infection to fatal respi …
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.
Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G; CTSN Investigators. Gammie JS, et al. N Engl J Med. 2022 Jan 27;386(4):327-339. doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13. N Engl J Med. 2022. PMID: 34767705 Free PMC article. Clinical Trial.
Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up. ...
Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follo …
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Van Mieghem NM, et al. JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695. JAMA Cardiol. 2022. PMID: 36001335 Free PMC article. Clinical Trial.
IMPORTANCE: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve was noninferior to surgery for all-cause mortality or disabling stroke at 2 years. Comparisons of longe …
IMPORTANCE: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with …
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.
Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Goldacre B, van Staa T, MacDonald TM, Armitage J, Wimborne J, Melrose P, Singh J, Brooks L, Moore M, Hoffman M, Smeeth L; StatinWISE Trial Group. Herrett E, et al. BMJ. 2021 Feb 24;372:n135. doi: 10.1136/bmj.n135. BMJ. 2021. PMID: 33627334 Free PMC article. Clinical Trial.
Two thirds of those completing the trial reported restarting long term treatment with statins. CONCLUSIONS: No overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo was found in participants who had previously reported severe muscle symptoms when ta …
Two thirds of those completing the trial reported restarting long term treatment with statins. CONCLUSIONS: No overall effect of ator …
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. Seppi K, et al. Among authors: fox sh. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. Mov Disord. 2011. PMID: 22021174 Free PMC article. Review.
As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication-related impuls …
As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different …
Levodopa-related motor complications--phenomenology.
Fox SH, Lang AE. Fox SH, et al. Mov Disord. 2008;23 Suppl 3:S509-14. doi: 10.1002/mds.22021. Mov Disord. 2008. PMID: 18781677 Review.
Long term levodopa therapy in Parkinson's disease (PD) results in a range of problems. ...
Long term levodopa therapy in Parkinson's disease (PD) results in a range of problems. ...
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
Rader F, Oręziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler T, Fox S, Balaratnam G, Sehnert AJ, Olivotto I. Rader F, et al. Among authors: fox s. JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. JACC Heart Fail. 2024. PMID: 38176782 Free article. Clinical Trial.
BACKGROUND: Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy are needed. OBJECTIVES: The authors sought to evaluate interim results from the EXPLORER-Long Term Extension (LTE) cohort of …
BACKGROUND: Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiom …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. Huot P, et al. Among authors: fox sh. Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Pharmacol Rev. 2013. PMID: 23319549 Review.
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term administration of L-DOPA is marred by the emergence of abnormal involuntary movements, i.e., L-DOPA-induced dyskinesia (LID). ...
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term …
Respite in Dementia: An Evolutionary Concept Analysis.
O' Shea E, Timmons S, O' Shea E, Fox S, Irving K. O' Shea E, et al. Among authors: fox s. Dementia (London). 2019 May;18(4):1446-1465. doi: 10.1177/1471301217715325. Epub 2017 Jun 28. Dementia (London). 2019. PMID: 28659025 Review.
This study provides clarification on the use and meaning of the term and considers the concept in relation to the dominant care paradigm in dementia, i.e. person-centred care. ...The key antecedent for a positive respite experience is that the carer perceives that mutual b …
This study provides clarification on the use and meaning of the term and considers the concept in relation to the dominant care parad …
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Gonzalez-Latapi P, et al. Among authors: fox sh. CNS Drugs. 2020 Oct;34(10):1025-1044. doi: 10.1007/s40263-020-00754-0. CNS Drugs. 2020. PMID: 32785890 Review.
To date, no non-dopaminergic selective drug has shown significant long-term efficacy as monotherapy in PD. The largest area of development in non-dopaminergic targets has been for motor complications of dopamine replacement therapy (motor fluctuations and dyskinesia). ...
To date, no non-dopaminergic selective drug has shown significant long-term efficacy as monotherapy in PD. The largest area of develo …
115 results